NASDAQ · FBIO

Fortress Biotech, Inc.

Healthcare · Biotechnology

$2.57▼ 2.28% ($0.06)at close

After hours$2.55▼ 0.93%7:30 PM ET

52-week

$2.18$4.53

Market cap

What the market price implies · Reverse DCF

Historical revenue grew by -2.07%/yr over the past 4 years.

Selected forecast · Base scenario

4.61%/yr · actual 10-year annualized revenue growth

Year 1 growth: 7.22%

Market-implied · Base operating assumptions + edited margins

Unavailable · flat 10-year annualized revenue growth

Reverse DCF solves revenue growth itself using Base operating assumptions and your edited margins. Changing forecast growth alone does not change the implied rate. This is a model-implied requirement, not an analyst forecast.

No supported revenue growth rate matches this price with these operating assumptions.

Valuation

Recommended · Revenue & margin DCF

Price used

$2.57

Estimated value / share

Unavailable

Base scenario

USD · TTM ending 2026-06-30

9 of 10 projected years produce negative free cash flow, so the model returns a negative enterprise value. A discounted-cash-flow valuation cannot be defended on those inputs, so it is not shown.

Reported operating earnings and the comparable cash-flow estimate differ substantially; the model retains the reported-margin anchor.

Year 1 growth 7.22% · Ending margin 0% · Discount rate 12.32%

Assumption scenarios, not statistical confidence intervals.

Method, dates & sources

Estimated from future revenue, operating margins, and the investment needed to support them.

Price timestamp: Sep 10, 2026, 8:00 PM UTC
Financial statement period: TTM ending 2026-06-30
Data refreshed: Sep 11, 2026, 4:28 AM UTC · provider

Why this method?

There is not a stable run of positive FCFF to anchor a direct cash-flow CAGR, so the model should start from revenue and margin assumptions instead.

Is FCFF positive and has it been for 3+ consecutive years? Latest FCFF is not positive.

Price vs Fundamentals

Why The Stock Is Moving

Likely multiple compressionModerate confidence

1Y Price: -33.42%Revenue (TTM): 15.46%FCF (TTM): 257.13%P/S: 51st pct

What changed

The stock fell 33.42% over the last year. Revenue grew 15.46% over the trailing twelve months. Operating margin moved from -182.51% to -42.86%. Free cash flow grew 257.13% over the trailing twelve months.

What the market seems to be pricing

Visible fundamentals weakened far less than the stock price. The market appears to be discounting durability, risk, or trust rather than just the latest reported numbers.

What would invalidate this read

This read changes if operating margin (currently -42.86%) continues to decline, or if revenue growth turns negative. The bull case requires the business to hold its current trajectory.

Performance

Return analysis

Company profile

Fortress Biotech, Inc. operates as a biopharmaceutical firm dedicated to the development and commercialization of a diverse range of pharmaceutical and biotechnology products.

CEOLindsay A. Rosenwald

SectorHealthcare

IndustryBiotechnology

Employees78

IPO dateNov 17, 2011

https://www.fortressbiotech.com

Market multiples

Forward P/E—

EV/EBITDA-4.81

Enterprise value$97.04M

Stock splits

Oct 10, 2023↓ Reverse

Every 15 shares became 1

-93%

Profitability & growth

Revenue growth14.04%

Gross margin62.53%▲3.1ppvs FY2024

Operating margin-42.86%▲80.4ppvs FY2024

ROE107.48%▲88.7ppvs FY2025

Analyst consensus

RatingBuy

Target price$5.00▲94.55%

Buy

Hold

Sell

Analyst ratings tend to be lagging indicators. Use as one signal among many.

Earnings

Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.

Next report

Nov 16, 2026

Q4 FY26 · EPS est -$0.27 · Revenue est $21.58M

View